Literature DB >> 18464105

Ikaros and acute leukemia.

Charles Mullighan1, James Downing.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18464105     DOI： 10.1080/10428190801947500

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  16 in total

1.  GATA-1 utilizes Ikaros and polycomb repressive complex 2 to suppress Hes1 and to promote erythropoiesis.

Authors:  Julie Ross; Lionel Mavoungou; Emery H Bresnick; Eric Milot
Journal:  Mol Cell Biol       Date:  2012-07-09       Impact factor: 4.272

Review 2.  Awakening lineage potential by Ikaros-mediated transcriptional priming.

Authors:  Toshimi Yoshida; Samuel Yao-Ming Ng; Katia Georgopoulos
Journal:  Curr Opin Immunol       Date:  2010-03-17       Impact factor: 7.486

3.  Up a lymphoid blind alley: Does CALM/AF10 disturb Ikaros during leukemogenesis?

Authors:  Philipp A Greif; Stefan K Bohlander
Journal:  World J Biol Chem       Date:  2011-06-26

Review 4.  Regulation of cellular proliferation in acute lymphoblastic leukemia by Casein Kinase II (CK2) and Ikaros.

Authors:  Chandrika Gowda; Chunhua Song; Malika Kapadia; Jonathon L Payne; Tommy Hu; Yali Ding; Sinisa Dovat
Journal:  Adv Biol Regul       Date:  2016-09-18

5.  Illegitimate RAG-mediated recombination events are involved in IKZF1 Δ3-6 deletion in BCR-ABL1 lymphoblastic leukaemia.

Authors:  Y Dong; F Liu; C Wu; S Li; X Zhao; P Zhang; J Jiao; X Yu; Y Ji; M Zhang
Journal:  Clin Exp Immunol       Date:  2016-07-28       Impact factor: 4.330

6.  Alternative promoter usage at the Notch1 locus supports ligand-independent signaling in T cell development and leukemogenesis.

Authors:  Pablo Gómez-del Arco; Mariko Kashiwagi; Audrey F Jackson; Taku Naito; Jiangwen Zhang; Feifei Liu; Barbara Kee; Marc Vooijs; Freddy Radtke; Juan Miguel Redondo; Katia Georgopoulos
Journal:  Immunity       Date:  2010-11-24       Impact factor: 31.745

Review 7.  Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.

Authors:  A Tefferi
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528

8.  Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia.

Authors:  I Iacobucci; A Ferrarini; M Sazzini; E Giacomelli; A Lonetti; L Xumerle; A Ferrari; C Papayannidis; G Malerba; D Luiselli; A Boattini; P Garagnani; A Vitale; S Soverini; F Pane; M Baccarani; M Delledonne; G Martinelli
Journal:  Blood Cancer J       Date:  2012-03-09       Impact factor: 11.037

9.  Expression of Ik6 and Ik8 Isoforms and Their Association with Relapse and Death in Mexican Children with Acute Lymphoblastic Leukemia.

Authors:  Adriana Reyes-León; Rocío Juárez-Velázquez; Alma Medrano-Hernández; Teresa Cuenca-Roldán; Consuelo Salas-Labadía; María Del Pilar Navarrete-Meneses; Roberto Rivera-Luna; Gerardo López-Hernández; Rogelio Paredes-Aguilera; Patricia Pérez-Vera
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

10.  PU.1 cooperates with IRF4 and IRF8 to suppress pre-B-cell leukemia.

Authors:  S H M Pang; M Minnich; P Gangatirkar; Z Zheng; A Ebert; G Song; R A Dickins; L M Corcoran; C G Mullighan; M Busslinger; N D Huntington; S L Nutt; S Carotta
Journal:  Leukemia       Date:  2016-03-02       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.